Clinical Trials Browser

Phase 3 × sintilimab × Clear all

NCT03607539 2026-05-11

Efficacy and Safety Evaluation of Sintilimab in Patients With Advanced or Metastatic Non-squamous NSCLC

Phase 3 Completed

397 enrolled 15 charts

Lung Neoplasms

NCT05357846 2026-04-30

PD-1 Inhibitor Combined With Neoadjuvant Chemoradiotherapy Plus Surgery for Locally Advanced ESCC (NEOCRTEC2101)

Phase 3 Recruiting

Gastrointestinal

Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms

NCT07537946 2026-04-17

Local Consolidation After Sintilimab Plus Lenvatinib for Metastatic Liver Cancer

Phase 3 Not yet recruiting

Gastrointestinal

Carcinoma, Hepatocellular, Neoplasm Metastasis

NCT04720716 2026-03-19

A Study to Compare the Effectiveness and Safety of IBI310 Combined With Sintilimab Versus Sorafenib in the First-line Treatment of Advanced HCC

Phase 3 Completed

Gastrointestinal

Carcinoma, Hepatocellular

NCT06497985 2026-03-19

A Study of Tucidinostat in Combination With Sintilimab and Bevacizumab in MSS/pMMR Colorectal Cancer Patients

Phase 3 Recruiting

Gastrointestinal

Colorectal Neoplasms

NCT07459296 2026-03-16

Becotatug Vedotin Plus Sintilimab in Locoregionally Advanced NPC

Phase 3 Recruiting

Nasopharyngeal Carcinoma

NCT05171660 2026-02-17

Combination With Sintilimab and XELOX+Bevacizumab as 1st Line Therapy in RAS-mutant Metastatic Colorectal Cancer

Phase 3 Active not recruiting

Gastrointestinal

Colorectal Neoplasms

NCT07371611 2026-01-28

Sintilimab Plus Chemotherapy as Neoadjuvant and Adjuvant Treatment for Locally Advanced Oral Squamous Cell Carcinoma

Phase 3 Recruiting

Squamous Cell Carcinoma of Head and Neck

NCT07306663 2025-12-29

ESO-Nanjing7

Phase 3 Active not recruiting

Gastrointestinal

Esophageal Neoplasms

NCT07186621 2025-09-22

Adjuvant Radiotherapy of Sintilimab Versus TACE for HCC

Phase 3 Recruiting

Gastrointestinal

Carcinoma, Hepatocellular

NCT05116462 2025-06-26

Neoadjuvant and Adjuvant Therapy Studies of Sindilizumab in Resectable Lung Cancer

Phase 3 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT06794086 2025-05-13

SPARKLE-L

Phase 3 Recruiting

Gastrointestinal

Colorectal Neoplasms

NCT06925243 2025-04-22

Neoadjuvant Apatinib Combined With Sintilimab and Perioperative SOX Versus Neoadjuvant Sintilimab Combined With Perioperative SOX for Intestinal Type of Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma

Phase 3 Recruiting

Gastrointestinal

Stomach Neoplasms

NCT06900218 2025-04-02

PD-1 Antibody Sintilimab Combined With Capecitabine as Adjuvant Therapy for High-Risk Nasopharyngeal Carcinoma

Phase 3 Not yet recruiting

Nasopharyngeal Carcinoma

NCT05549037 2025-02-19

PACIFIC15

Phase 3 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT06584032 2025-01-07

Study of Fruquintinib Plus Sintilimab for Treatment of Advanced Endometrial Cancer

Phase 3 Recruiting

Endometrial Neoplasms

NCT05495152 2024-10-02

Adjuvant Sintilimab for Locally Advanced Esophageal Squamous Cell Carcinoma

Phase 3 Recruiting

Gastrointestinal

Esophageal Squamous Cell Carcinoma

NCT06485557 2024-07-03

A Prospective Cohort Study of Neoadjuvant Chemotherapy Plus Sintillumab in the Treatment of Resectable NSCLC

Phase 3 Not yet recruiting

Resectable Non-small Cell Lung Cancer

NCT06089369 2024-04-30

Postoperative Adjuvant Sintilimab in Hepatocellular Carcinoma With Microvascular Invasion

Phase 3 Not yet recruiting

Gastrointestinal

Carcinoma, Hepatocellular

NCT05890742 2024-03-15

A Clinical Trial Evaluating the Efficacy and Safety of IBI310 in Combination With Sintilimab, for Neoadjuvant Treatment of MSI-H/dMMR Resectable Colon Cancer

Phase 3 Recruiting

Other solid neoplasm

MSI-H

NCT05918094 2024-01-26

Comparing Modified XELOX Plus Sintilimab With Standard XELOX Plus Sintilimab in First-line Treatment for HER2-negative Gastric/Gastroesophageal Junction Adenocarcinoma

Phase 3 Recruiting

Gastrointestinal

Stomach Neoplasms

NCT06161909 2023-12-08

Postoperative Immune Maintenance Therapy for Esophageal Squamous Cell Carcinoma After Radical Resection

Phase 3 Unknown

Gastrointestinal

Esophageal Neoplasms

NCT03802240 2023-11-27

Sintilimab ± IBI305 Plus Chemotherapy (Pemetrexed + Cisplatin) for EGFRm + Locally Advanced or Metastasis Non-Squamous NSCLC Patients After EGFR-TKI Treatment Failure

Phase 3 Completed

Non-Squamous Non-Small Cell Lung Cancer

NCT03748134 2023-10-24

Sintilimab or Placebo With Chemotherapy in Esophageal Squamous Cell Carcinoma ( ORIENT-15 )

Phase 3 Completed

Gastrointestinal

Esophageal Squamous Cell Carcinoma, Carcinoma, Squamous Cell, Esophageal Diseases, Esophageal Neoplasms, Gastrointestinal Diseases, Neoplasms, Squamous Cell

NCT06089382 2023-10-18

A Study to Evaluate Sintilimab Plus Lenvatinib as Adjuvant Therapy in Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis (PVTT) After Surgical Resection

Phase 3 Not yet recruiting

Gastrointestinal

Carcinoma, Hepatocellular

NCT06031597 2023-09-13

Radiotherapy Combined With ICIs as Treatment for LA-NSCLC After Failing Induction Immunochemotherapy

Phase 3 Unknown

Carcinoma, Non-Small-Cell Lung, Radiation Pneumonitis

NCT05608200 2023-05-31

Lenvatinib+Sintilimab+TACE vs. Lenvatinib+TACE for Advanced HCC

Phase 3 Recruiting

Gastrointestinal

Carcinoma, Hepatocellular

NCT03700476 2023-03-28

CONTINUUM

Phase 3 Unknown

Nasopharyngeal Neoplasms

NCT03745170 2023-03-01

Efficacy and Safety Evaluation of Sintilimab or Placebo in Combination With XELOX as First Line Treatment in Patients With Gastric Cancer

Phase 3 Completed

Gastrointestinal

Stomach Neoplasms

NCT03150875 2023-02-28

A Study Comparing the Efficacy and Safety Between IBI308 and Docetaxel in Patients With Advanced or Metastatic NSCLC

Phase 3 Completed

290 enrolled 14 charts

Carcinoma, Non-Small-Cell Lung

NCT03629925 2023-02-28

Sintilimab in Combination With Gemcitabine and Platinum-Based Chemotherapy as First-Line Therapy for Advanced or Metastatic Squamous NSCLC

Phase 3 Completed

357 enrolled 14 charts

Squamous NSCLC

NCT05236972 2022-12-30

PACE: PD-1 Antibody For dMMR/MSI-H Stage III Colorectal Cancer

Phase 3 Recruiting

Gastrointestinal

Colorectal Neoplasms

NCT05429463 2022-12-14

neoSCORE Ⅱ

Phase 3 Recruiting

Squamous Cell Non-small Cell Lung Cancer

NCT05648071 2022-12-13

SPBPDC

Phase 3 Unknown

Advanced Non-squamous Non-Small-Cell Lung Cancer

NCT05244798 2022-10-25

Sintilimab Plus NCT or NCRT Versus NCRT for ESCC

Phase 3 Not yet recruiting

Gastrointestinal

Esophageal Squamous Cell Carcinoma

NCT05429684 2022-06-23

Precise Therapy for Refractory HER2 Positive Advanced Breast Cancer

Phase 3 Unknown

HER2+ Breast Cancer